ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia
Open accessThe DOI matches its Crossref record; 4 of the 5 references it cites were found in a registry or an index.
Abstract
Evinacumab, a monoclonal antibody that blocks ANGPTL3, was administered to nine adults with homozygous familial hypercholesterolemia. At 4 weeks, LDL cholesterol was reduced by a mean of 49%, with a mean absolute change from baseline of −157 mg per deciliter.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several novel therapies that potently reduce triglyceride levels are currently in development.[6][7][8]”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [7]
In the citing paper
“It is of particular interest that, contrary to other lipid-lowering drugs, such as PCSK9 inhibitors,21,22 the lipid lowering effect of ANGPTL3 inhibition by evinacumab seems to be independent of the presence of residual LDLR activity, supporting the data obtained in animal models,6,10 as well as in a pilot clinical trial.9”
In the citing paper
“Interestingly, the LDL-C lowering effects of ANGPTL3 inhibition with either monoclonal antibodies or antisense oligonucleotides seems to be LDL receptor (LDLR) independent since marked LDL-C lowering is observed in both Ldlr knock-out (KO) mice6,8 and patients with homozygous familial hypercholesterolemia (hoFH).9”
In the citing paper
“Interestingly, the LDL-C lowering effects of ANGPTL3 inhibition with either monoclonal antibodies or antisense oligonucleotides seems to be LDL receptor (LDLR) independent since marked LDL-C lowering is observed in both Ldlr knock-out (KO) mice6,8 and patients with homozygous familial hypercholesterolemia (hoFH).9”
In the citing paper
“Based on the data collected during the parent clinical trials and other studies, LDL-C levels typically reach nadir after 4 weeks of receiving evinacumab infusion and remain generally stable at week 6.9”
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Cuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu274 · Cited by 1,057
Self-citationGenetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885
Self-citationExome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia
Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K. V., Fisher, S., Abreu, J., Barry, A. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002926 · Cited by 754
Rader, D. J., & Kastelein, J. J. P. (2014) · Circulation · doi:10.1161/circulationaha.113.001292 · Cited by 264
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“Evinacumab has been shown to decrease TGs, LDL-C, and Lp(a) levels in HoFH patients.(344) Another approach that is currently being investigated is the inhibition of ANGPTL3 production by antisense oligonucleotides.”
Inflammation and atherosclerosis: signaling pathways and therapeutic intervention
Kong, P., Cui, Z.-Y., Huang, X.-F., Zhang, D.-D., Guo, R.-J., & Han, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00955-7 · Cited by 1,183
“In patients with homozygous familial hypercholesterinaemia, evinocumab could reduce the level of plasma LDL from 20% to 90% and TG ~50%.(291) On the other hand, ANGPTL3-specific antisense oligonucleotides (ASOs) could inhibit ANGPTL3 synthesis.”
BackgroundEvinacumab for Homozygous Familial Hypercholesterolemia
Raal, F. J., Rosenson, R. S., Reeskamp, L. F., Hovingh, G. K., Kastelein, J. J. P., Rubba, P., Ali, S., Banerjee, P., Chan, K.-C., Gipe, D. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004215 · Cited by 793
Self-citationFerence, B. A., Kastelein, J. J. P., Ray, K. K., Ginsberg, H. N., Chapman, M. J., Packard, C. J., Laufs, U., Oliver-Williams, C., Wood, A. M., Butterworth, A. S., et al. (2019) · JAMA · doi:10.1001/jama.2018.20045 · Cited by 703
Clinical review on triglycerides
Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz785 · Cited by 544
“Among homozygous familial hypercholesterolaemia patients, evinacumab reduced LDL-C, TG and HDL-C by 49%, 47%, and 36%, respectively.(81) IONIS-ANGPTL3-LRx is a GalNac-modified ASO that targets ANGPTL3.”
BackgroundHypertriglyceridemia and acute pancreatitis
Yang, A. L., & McNabb-Baltar, J. (2020) · Pancreatology · doi:10.1016/j.pan.2020.06.005 · Cited by 333
Evinacumab in Patients with Refractory Hypercholesterolemia
Rosenson, R. S., Burgess, L. J., Ebenbichler, C. F., Baum, S. J., Stroes, E. S. G., Ali, S., Khilla, N., Hamlin, R., Pordy, R., Dong, Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2031049 · Cited by 302
Self-citationDiagnosis and Treatment of Heterozygous Familial Hypercholesterolemia
McGowan, M. P., Hosseini Dehkordi, S. H., Moriarty, P. M., & Duell, P. B. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013225 · Cited by 271
Ahmad, Z., Banerjee, P., Hamon, S., Chan, K.-C., Bouzelmat, A., Sasiela, W. J., Pordy, R., Mellis, S., Dansky, H., Gipe, D. A., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.039107 · Cited by 246
“36 Patients with biallelic null LDL receptor mutations had a 34% drop in LDL-C on evinacum-ab.”
InfluentialSelf-citationAdam, R. C., Mintah, I. J., Alexa-Braun, C. A., Shihanian, L. M., Lee, J. S., Banerjee, P., Hamon, S. C., Kim, H. I., Cohen, J. C., Hobbs, H. H., et al. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra120000888 · Cited by 208
“blockade lowers LDL-C independently of LDLR (23, 24), providing a new therapeutic avenue for the treatment of FH (25).”
Self-citationLeveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease
Romeo, S., Sanyal, A., & Valenti, L. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.12.002 · Cited by 202
Hegele, R. A., Borén, J., Ginsberg, H. N., Arca, M., Averna, M., Binder, C. J., Calabresi, L., Chapman, M. J., Cuchel, M., von Eckardstein, A., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30264-5 · Cited by 204
Self-citationFamilial hypercholesterolemia treatments: Guidelines and new therapies
Raal, F. J., Hovingh, G. K., & Catapano, A. L. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.859 · Cited by 194
Self-citationLong-Term Evolocumab in Patients With Familial Hypercholesterolemia
Santos, R. D., Stein, E. A., Hovingh, G. K., Blom, D. J., Soran, H., Watts, G. F., López, J. A. G., Bray, S., Kurtz, C. E., Hamer, A. W., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.12.020 · Cited by 186
“Additional candidates under development include antibodies to ANGPTL3 (28).”
BackgroundSelf-citationEvolocumab in Pediatric Heterozygous Familial Hypercholesterolemia
Santos, R. D., Ruzza, A., Hovingh, G. K., Wiegman, A., Mach, F., Kurtz, C. E., Hamer, A., Bridges, I., Bartuli, A., Bergeron, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2019910 · Cited by 192
Self-citationLipid-Lowering Agents: Targets Beyond PCSK9
Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171
“Treatment resulted in mean reductions in LDL-C, TG, and HDL-C of 49%, 47%, and 36%, respectively.(146) Thus, evinacumab seems to be effective in”
BackgroundEfficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia
Blom, D. J., Harada-Shiba, M., Rubba, P., Gaudet, D., Kastelein, J. J. P., Charng, M.-J., Pordy, R., Donahue, S., Ali, S., Dong, Y., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.027 · Cited by 166
Self-citationRegulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8
Sylvers-Davie, K. L., & Davies, B. S. J. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00195.2021 · Cited by 154
Advances in lipid-lowering therapy through gene-silencing technologies
Nordestgaard, B. G., Nicholls, S. J., Langsted, A., Ray, K. K., & Tybjærg‐Hansen, A. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2018.3 · Cited by 156
Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care
Watts, G. F., Gidding, S. S., Mata, P., Pang, J., SULLIVAN, D. R., Yamashita, S., Raal, F. J., Santos, R. D., & Ray, K. K. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0325-8 · Cited by 154
Rosenson, R. S., Gaudet, D., Ballantyne, C. M., Baum, S. J., Bergeron, J., Kershaw, E. E., Moriarty, P. M., Rubba, P., Whitcomb, D. C., Banerjee, P., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02222-w · Cited by 140
Self-citationLu, Y., Cui, X., Zhang, L., Wang, X., Xu, Y., Qin, Z., Liu, G., Wang, Q., Tian, K., Lim, K. S., et al. (2022) · Aging and Disease · doi:10.14336/ad.2021.0929 · Cited by 131
“Evinacumab is particularly beneficial for patients with LDL receptor mutations, as its effects to reduce LDL-C are independent of LDL receptors as demonstrated by a 34% reduction in LDL-C of patients with biallelic null LDL receptor mutations [144].”
BackgroundNew and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B
Nurmohamed, N. S., Návar, A. M., & Kastelein, J. J. P. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.079 · Cited by 131
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
“After evinacumab’s proof of concept was established in a single-group phase 2 trial [149], the phase 3 ELIPSE trial was conducted [150].”
BackgroundReeskamp, L. F., Millar, J. S., Wu, L., Jansen, H., van Harskamp, D., Schierbeek, H., Gipe, D. A., Rader, D. J., Dallinga-Thie, G. M., Hovingh, G. K., et al. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.315204 · Cited by 109
Self-citationTargeting RNA With Antisense Oligonucleotides and Small Interfering RNA in Dyslipidemias
Katzmann, J. L., Packard, C. J., Chapman, M. J., Katzmann, I., & Laufs, U. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.070 · Cited by 99
Banerjee, P., Chan, K.-C., Tarabocchia, M., Benito-Vicente, A., Alves, A. C., Uribe, K. B., Bourbon, M., Skiba, P. J., Pordy, R., Gipe, D. A., et al. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313051 · Cited by 97
“19 Among the new treatments approved for lowering LDL-C are evolocumab and alirocumab, both monoclonal antibodies that prevent circulating PCSK9 from binding to the LDL receptor.”
Self-citationNew insights into angiopoietin-like proteins in lipid metabolism and cardiovascular disease risk
Kersten, S. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000600 · Cited by 94
A new dawn for managing dyslipidemias: The era of rna-based therapies
Macchi, C., Sirtori, C. R., Corsini, A., Santos, R. D., Watts, G. F., & Ruscica, M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104413 · Cited by 94
Thermostable ionizable lipid-like nanoparticle (iLAND) for RNAi treatment of hyperlipidemia
Hu, B., Li, B., Li, K., Liu, Y., Li, C., Zheng, L., Zhang, M., Yang, T., Guo, S., Dong, X., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm1418 · Cited by 92
“With further development, it is accepted that the onset of hyperlipidemia is usually accompanied by the abnormal expression of certain genes, such as proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) ( 8 ), angiopoietin-like 3 ( ANGPTL3 ) ( 9 ), and apolipoprotein C3 ( ApoC3 ) ( 10 ).”
Ray, K. K., Corral, P., Morales, E., & Nicholls, S. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31950-6 · Cited by 94
Zhang, R., & Zhang, K. (2022) · Progress in Lipid Research · doi:10.1016/j.plipres.2021.101140 · Cited by 90
Familial Chylomicronemia Syndrome: A Clinical Guide for Endocrinologists
Falko, J. M. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0157 · Cited by 93
Kersten, S. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000789 · Cited by 83
“&& Raal FJ, Rosenson RS, Reeskamp LF, et al., ELIPSE HoFH Investigators.”
ResultInfluentialHypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding
Sniderman, A. D., Couture, P., Martin, S. S., DeGraaf, J., Lawler, P. R., Cromwell, W. C., Wilkins, J. T., & Thanassoulis, G. (2018) · Journal of Lipid Research · doi:10.1194/jlr.r082271 · Cited by 92
“(61) confirmed that ANGPTL3 could produce a substantial reduction in LDL and apoB, an effect that in these patients must be mediated by a mechanism other than enhanced LDL receptor clearance.”
BackgroundRuscica, M., Zimetti, F., Adorni, M. P., Sirtori, C. R., Lupo, M. G., & Ferri, N. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104653 · Cited by 82
Ginsberg, H. N., & Goldberg, I. J. (2023) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.122.317966 · Cited by 80
Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis
Zhang, B., Yin, F., Qiao, Y.-N., & Guo, S. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.909151 · Cited by 105
Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy
Gaudet, D., Greber‐Platzer, S., Reeskamp, L. F., Iannuzzo, G., Rosenson, R. S., Saheb, S., Stefanutti, C., Stroes, E. S. G., Wiegman, A., Turner, T. A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae325 · Cited by 92
Self-citationUnderberg, J. A., Cannon, C. P., Larrey, D. G., Makris, L., Blom, D. J., & Phillips, H. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.08.006 · Cited by 83
Lotta, L. A., Stewart, I. D., Sharp, S. J., Day, F. R., Burgess, S., Luan, J., Bowker, N., Cai, L., Li, C., Wittemans, L. B. L., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.2866 · Cited by 72
“Inphase 1 trials,ANGPTL3 inhibitors reducedLDL-C levelsbyamounts similar toorgreater thancurrentlyapproved LDL-C–loweringdrugs.(6,20,21)Ourfindingssuggest thatANGPTL3 inhibitorsmaybemoreeffective thancurrentagents foragiven magnitude of LDL-C reduction.”
BackgroundStahel, P., Xiao, C., Hegele, R. A., & Lewis, G. F. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.007 · Cited by 75
Lipid Lowering Drugs: Present Status and Future Developments
Ruscica, M., Ferri, N., Santos, R. D., Sirtori, C. R., & Corsini, A. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00918-3 · Cited by 73
How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol
Karagiannis, A. D., Mehta, A., Dhindsa, D. S., Virani, S. S., Orringer, C. E., Blumenthal, R. S., Stone, N. J., & Sperling, L. S. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa1080 · Cited by 81
“An antiANGPTL3 antibody (evinacumab) and an antisense oligonucleotide targeting ANGPTL3-mRNA are currently undergoing clinical trials for the management of dyslipidaemias.(119,120) An MTP inhibitor (lomitapide) and an ApoB-100 mRNA inhibitor (mipomersen) significantly reduced LDL-C in patients with Homozygous Familial”
BackgroundCholesterol metabolism related genes in osteoarthritis
Papathanasiou, I. V., Anastasopoulou, L., & Tsezou, A. (2021) · Bone · doi:10.1016/j.bone.2021.116076 · Cited by 72
LDL-Cholesterol Reduction by ANGPTL3 Inhibition in Mice Is Dependent on Endothelial Lipase
Wu, L., Soundarapandian, M. M., Castoreno, A. B., Millar, J. S., & Rader, D. J. (2020) · Circulation Research · doi:10.1161/circresaha.120.317128 · Cited by 70
Advances in biological therapies for dyslipidemias and atherosclerosis
Valanti, E.-K., Dalakoura-Karagkouni, K., Siasos, G., Kardassis, D., Eliopoulos, A. G., & Sanoudou, D. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154461 · Cited by 72
Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events
Raschi, E., Casula, M., Cicero, A. F. G., Corsini, A., Borghi, C., & Catapano, A. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108507 · Cited by 59
Novel emerging therapies in atherosclerosis targeting lipid metabolism
Gupta, M., Blumenthal, C., Chatterjee, S., Bandyopadhyay, D., Jain, V., Lavie, C. J., Virani, S. S., Ray, K. K., Aronow, W. S., & Ghosh, R. K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1764937 · Cited by 75
“Although mipomersen has been shown to have efficacy in reducing apo-B-related lipoproteins among patients with different types of hypercholesterolemia [44–46], its approval is still strictly limited to HoFH as an orphan drug.”
BackgroundInfluentialHypertriglyceridemia—causes, significance, and approaches to therapy
Santos-Baez, L. S., & Ginsberg, H. N. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00616 · Cited by 66
Pouwer, M. G., Pieterman, E. J., Worms, N., Keijzer, N., Jukema, J. W., Gromada, J., Gusarova, V., & Princen, H. M. G. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra119000419 · Cited by 66
“The ANGPTL3 monoclonal antibody, evinacumab, was reported to reduce plasma TG and LDL-C levels in healthy subjects and patients with homozygous familial hypercholesterolemia (18, 30).”
BackgroundSelf-citationAngiopoietin-Like 3 (ANGPTL3) and Atherosclerosis: Lipid and Non-Lipid Related Effects
Lupo, M. G., & Ferri, N. (2018) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd5030039 · Cited by 63
“Two of them, the full-human monoclonal antibody evinacumab [77,78] and antisense oligonucleotide [79], have proven positive effects on the lipid profile both in pre-clinical trials in murine models and in phase I trial in healthy volunteers and patients affected by homozygous familial hypercholesterolemia.”
BackgroundManagement of Familial Hypercholesterolemia: Current Status and Future Perspectives
Lui, D. T. W., Lee, A. C. H., & Tan, K. C. B. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa122 · Cited by 68
“A singlearm, open-label study in 9 patients with HoFH or compound HeFH showed that evinacumab significantly reduced LDL-C by a mean of 49% after 4 weeks of treatment, and it was also effective in 3 patients with null/null LDLR genotypes [127] (Table 3).”
ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets
Akoumianakis, I., Zvintzou, E., Kypreos, K. E., & Filippatos, T. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00914-7 · Cited by 70
“…in TG up to 55.5% for all single SC doses, up to 80.3% for single IV doses, up to 88.2% for multiple IV doses and up to 51.9% for multiple SC doses D Gaudet et al. 2017 [45•] Phase 2 open label single-group, homozygous FH adults Evinacumab (monoclonal antibody) Evinacumab SC 250 mg at baseline…”
BackgroundInfluentialMarkham, A. (2021) · Drugs · doi:10.1007/s40265-021-01516-y · Cited by 64
“Inhibition of ANGPTL3 preserves the activity of LPL and EL, leading to reduced TG, LDL-C and HDL-C levels in plasma, independently of the LDL receptor [3, 4].”
BackgroundLipid lowering therapy in cardiovascular disease: From myth to molecular reality
Mourikis, P., Zako, S., Dannenberg, L., Nia, A. M., Heinen, Y., Busch, L., Richter, H., Hohlfeld, T., Zeus, T., Kelm, M., et al. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107592 · Cited by 63
Therapeutic RNA-silencing oligonucleotides in metabolic diseases
Goga, A., & Stoffel, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00407-5 · Cited by 58
ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases
Luo, F., Das, A., Khetarpal, S. A., Fang, Z., Zelniker, T. A., Rosenson, R. S., & Qamar, A. (2024) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2023.01.008 · Cited by 58
Apolipoprotein C-II: the re-emergence of a forgotten factor
Wolska, A., Reimund, M., & Remaley, A. T. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000680 · Cited by 52
Ahmad, Z., Pordy, R. C., Rader, D. J., Gaudet, D., Ali, S., Gonzaga-Jauregui, C. G., Ponda, M. P., Shumel, B. S., Banerjee, P., & Dunbar, R. L. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.04.091 · Cited by 59
Self-citationWang, X., & Musunuru, K. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.05.008 · Cited by 62
“They received the antibody for 4 weeks, and their LDL-C levels were decreased by w50% at week 4, although the patients were already taking aggressive lipid-lowering therapy (32).”
BackgroundBlom, D. J., Raal, F. J., Santos, R. D., & Marais, A. D. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0809-3 · Cited by 62
Morinaga, J., Zhao, J., Endo, M., Kadomatsu, T., Miyata, K., Sugizaki, T., Okadome, Y., Tian, Z., Horiguchi, H., Miyashita, K., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0193731 · Cited by 54
Harada-Shiba, M., Ali, S., Gipe, D. A., Gasparino, E., Son, V., Zhang, Y., Pordy, R., & Catapano, A. L. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.10.013 · Cited by 52
Self-citationModeling hypercholesterolemia and vascular lipid accumulation in LDL receptor mutant zebrafish
Liu, C., Kim, Y. S., Kim, J., Pattison, J., Kamaid, A., & Miller, Y. I. (2018) · Journal of Lipid Research · doi:10.1194/jlr.d081521 · Cited by 54
“addition, an antibody targeting angiopoietin-like 3 resulted in a significant reduction of LDL-C in homozygous FH patients (10).”
BackgroundCurrent Options and Future Perspectives in the Treatment of Dyslipidemia
Muscoli, S., Ifrim, M., Russo, M., Candido, F., Sanseviero, A., Milite, M., Luozzo, M. D., Marchei, M., & Sangiorgi, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164716 · Cited by 56
“It also reduced apoB, nonHDL-C, triglyceride and HDL-C levels by an average of 46% ± 18%, 49% ± 22%, 47%, and 36% ± 16%, respectively [83].”
BackgroundA unified model for regulating lipoprotein lipase activity
Zhang, R., & Zhang, K. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.02.016 · Cited by 56
Sterol Metabolism and Transport in Atherosclerosis and Cancer
Yamauchi, Y., & Rogers, M. A. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00509 · Cited by 55
“While outcomes are not known, inhibition of the lipoprotein lipase inhibitor, angiopoitein-like 3 reduces circulating cholesterol, notably in homozygous familial hypercholesterolemia patients that only have limited responses to statin and PCSK9 therapies, and who typically require arduous LDL apheresis treatment (207).”
BackgroundEvinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia
Sosnowska, B., Adach, W., Surma, S., Rosenson, R. S., & Banach, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010168 · Cited by 50
“All subjects were administered evinacumab at doses of 250 mg SC and 15 mg/kg IV after 2 weeks [27].”
BackgroundMethodInfluentialRecent Treatment Strategies for Acute Pancreatitis
Song, Y., & Lee, S. H. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13040978 · Cited by 64
Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2025
Rached, F. H., Miname, M. H., Rocha, V. Z., Zimerman, A., Cesena, F. Y., Sposito, A. C., Santos, R. D., Behr, P. E. B., Bianco, H. T., Alves, R. J., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250640 · Cited by 98
ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis
Mohamed, F., Mansfield, B. S., & Raal, F. J. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01071-1 · Cited by 48
Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data
Strilchuk, L., Fogacci, F., & Cicero, A. F. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1620730 · Cited by 47
Familial Hypercholesterolemia and Lipoprotein Apheresis
Makino, H., Koezuka, R., Tamanaha, T., Ogura, M., Matsuki, K., Hosoda, K., & Harada‐Shiba, M. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17033 · Cited by 53
Familial Hypercholesterolaemia in 2020: A Leading Tier 1 Genomic Application
Pang, J., SULLIVAN, D. R., Brett, T., Kostner, K., Hare, D. L., & Watts, G. F. (2019) · Heart Lung and Circulation · doi:10.1016/j.hlc.2019.12.002 · Cited by 50
Chyzhyk, V., & Brown, A. S. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.03.001 · Cited by 49
Angiopoietin-like protein 3 (ANGPTL3) deficiency and familial combined hypolipidemia
Tarugi, P., Bertolini, S., & Calandra, S. (2018) · Journal of Biomedical Research · doi:10.7555/jbr.32.20170114 · Cited by 47
“[58] Gaudet D, Gipe DA, Pordy R, et al.”
BackgroundCurrent Diagnosis and Management of Primary Chylomicronemia
Okazaki, H., Gotoda, T., Ogura, M., Ishibashi, S., Inagaki, K., Daida, H., Hayashi, T., Hori, M., Masuda, D., Matsuki, K., et al. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17054 · Cited by 48
Familial combined hypolipidemia: angiopoietin-like protein-3 deficiency
Arca, M., D’Erasmo, L., & Minicocci, I. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000668 · Cited by 43
“Moreover, the addition of evinacumab to current treatments in nine patients with homozygous familial hypercholesterolemia (HoFH) for 4 weeks resulted in substantial reductions in LDL-C, triglyceride and HDL-C levels by 50, 47, and 36% respectively [23,26].”
BackgroundThe Regulation of Triacylglycerol Metabolism and Lipoprotein Lipase Activity
Wen, Y., Chen, Y., & Konrad, R. J. (2022) · Advanced Biology · doi:10.1002/adbi.202200093 · Cited by 53
Landfors, F., Henneman, P., Chorell, E., Nilsson, S. K., & Kersten, S. (2024) · European Heart Journal Open · doi:10.1093/ehjopen/oeae035 · Cited by 42
Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia
Nurmohamed, N. S., Dallinga‐Thie, G. M., & Stroes, E. S. G. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1768848 · Cited by 43
“In a phase II proof-of concept trial involving nine patients with familial hypercholesterolemia (FH), a median reduction in TG of 47% was achieved next to the LDL-C reduction between 25% and 90% [83].”
BackgroundOlkkonen, V. M., Sinisalo, J. P., & Jauhiainen, M. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.03.019 · Cited by 44
Update on Therapeutic Options in Lipodystrophy
Akıncı, B., Meral, R., & Oral, E. A. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1100-7 · Cited by 42
ANGPTL3 Inhibitors ― Their Role in Cardiovascular Disease Through Regulation of Lipid Metabolism ―
Geladari, E. V., Tsamadia, P., & Vallianou, N. G. (2018) · Circulation Journal · doi:10.1253/circj.cj-18-0442 · Cited by 44
ANGPTL3: a novel biomarker and promising therapeutic target
Jiang, S., Qiu, G.-H., Zhu, N., Hu, Z., Liao, D., & Li, Q. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2019.1566342 · Cited by 43
“Evinacumab Biological agents Directly Lipid-lowering targets the circulating ANGPTL3 protein Phase III trials [49,84]”
BackgroundPirillo, A., Catapano, A. L., & Norata, G. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00972-x · Cited by 46
Srivastava, R. A. K. (2023) · Cells · doi:10.3390/cells12121648 · Cited by 48
“iting the function of apoC-III [95] and angiopoietin like-3 protein (ANGPTL-3) [52,55]”
BackgroundInfluentialReeskamp, L. F., Tromp, T. R., & Stroes, E. S. G. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000679 · Cited by 36
“Evinacumab was subsequently administered to nine homozygous familial hypercholesterolemia patients, which resulted in a mean LDL-C reduction of almost 50% [36].”
Novel and Emerging LDL-C Lowering Strategies: A New Era of Dyslipidemia Management
Agnello, F., Ingala, S., Laterra, G., Scalia, L., & Barbanti, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051251 · Cited by 39
“A phase II trial conducted in 9 adults with homozygous familial hypercholesterolemia, on maximum of tolerated LLT, showed the efficacy of evinacumab, with a mean reduction in LDL-C levels by 49% after 4 weeks [62].”
Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors
Tomlinson, B., Wu, Q., Zhong, Y.-M., & Li, Y. (2024) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2024.13.1.2 · Cited by 47
“31 At week 4, the mean (±SD) reductions in lipids levels were 49±23% in LDL-C, 46±18% in apoB, 49±22% in non-HDL cholesterol, 36±16% in HDL-C and a median of 47% (interquartile range, 38% to 57”
BackgroundGaudet, D., Gonciarz, M. D., Xi Zhong, S. H. E. N., Leohr, J. K., Beyer, T. P., Day, J. W., Mullins, G. R., Zhen, Y., Hartley, M., Larouche, M., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03830-4 · Cited by 41
Self-citationBchetnia, M., Bouchard, L., Mathieu, J., Campeau, P. M., Morin, C., Brisson, D., Laberge, A., Vézina, H., Gaudet, D., & Laprise, C. (2021) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2021-107809 · Cited by 50
Self-citationZuurbier, L. C., Defesche, J. C., & Wiegman, A. (2021) · Genes · doi:10.3390/genes12081168 · Cited by 40
“Whereas ANGPTL3 siRNAs are still in phase one studies, monoclonal antibodies showed in 65 homozygous FH patients who did not achieve target LDL a similar positive effect as observed in vitro [79,80].”
BackgroundLowering low-density lipoprotein cholesterol: from mechanisms to therapies
Luo, J., Wang, J.-K., & Song, B.-L. (2022) · Life Metabolism · doi:10.1093/lifemeta/loac004 · Cited by 36
Evidence for improved survival with treatment of homozygous familial hypercholesterolemia
Bélanger, A. M., Akioyamen, L. E., Alothman, L., & Genest, J. J. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000686 · Cited by 38
New Insights Into the Treatment of Hyperlipidemia: Pharmacological Updates and Emerging Treatments
Abbasi, S., Khan, A. A., & Choudhry, M. W. (2024) · Cureus · doi:10.7759/cureus.63078 · Cited by 49
Thambiah, S. C., & Lai, L. C. (2021) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2021.e00248 · Cited by 52
Kosmas, C. E., Bousvarou, M. D., Sourlas, A., Papakonstantinou, E. J., Peña Genao, E., Echavarria Uceta, R., & Guzman, E. (2022) · Clinical Pharmacology: Advances and Applications · doi:10.2147/cpaa.s345072 · Cited by 34
“In addition, levels of ApoB, non-HDL-C, TG and HDL-C were reduced by 46±18%, 49±22%, 47% and 36±16%, respectively.(33) A small, recently completed study, enrolled four subjects already participating in the above-mentioned study in order to assess the catabolic rate of ApoB lipoproteins before and after receiving evina…”
Result
Metadata
- Authors
- Gaudet, D., Gipe, D. A., Pordy, R., Ahmad, Z., Cuchel, M., Shah, P. K., Chyu, K.-Y., Sasiela, W. J., Chan, K.-C., Brisson, D., Khoury, E., Banerjee, P., Gusarova, V., Gromada, J., Stahl, N., Yancopoulos, G. D., & Hovingh, G. K.
- Affiliations
- Université de Montréal (CA)
- Regeneron (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- University of Pennsylvania (US)
- Cedars-Sinai Medical Center (US)
- University of Amsterdam (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-07-20
- Volume
- 377
- Issue
- 3
- Pages
- 296-297
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2738009647
- Cited by
- 323
- References
- 5
- Citations by year
- 2026: 13 · 2025: 26 · 2024: 29 · 2023: 23 · 2022: 41 · 2021: 58 · 2020: 62 · 2019: 36 · 2018: 30 · 2017: 4
- FWCI
- 36.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- ANGPTL3, evinacumab, homozygous familial hypercholesterolemia, LDL cholesterol lowering, monoclonal antibodies, cholesterol absorption inhibition, lipid-lowering therapy
- MeSH terms
- Angiopoietin-like Proteins, Angiopoietin-Like Protein 3, Antibodies, Monoclonal, Genotype, Humans, Hyperlipoproteinemia Type II, Cholesterol, LDL, Receptors, LDL, Angiopoietins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.